HLA-C and neoplasm: Therefore, defining the optimal avidity range of neoantigen-specific TCRs to provide durable clinical benefit, and the factors that influence that range, remains a complicated issue, particularly because target epitope:MHC expression can be heterogeneous within the tumor.